DEXA-PSYCH研究——地塞米松治疗中重度抑郁:双盲、随机、平行组、安慰剂对照试验的研究方案
DEXA-PSYCH是一项由研究者发起的双盲、随机、平行组、安慰剂对照优效性试验,计划纳入300例中重度抑郁患者,按1:1随机接受1周口服地塞米松(4 mg/日×4天,随后2 mg/日×3天)或安慰剂作为常规治疗的附加治疗。主要结局为第7天蒙哥马利-阿斯伯格抑郁评定量表(MADRS)评分较基线的变化,采用意向性分析中的重复测量混合模型分析。
要点
- 300例中重度抑郁患者按1:1随机接受1周口服地塞米松或安慰剂附加治疗。
- 主要结局为第7天MADRS评分较基线变化,采用MMRM意向性分析。
- 关键次要结局包括应答率、缓解率、干预后3周疗效、生活质量及安全性。
核心结论
- DEXA-PSYCH试验是全球同类试验中规模最大的,若证实既往较小研究的发现,当需要急性抗抑郁效应时,短期口服地塞米松可能成为一种有吸引力的增效策略。
- 地塞米松是一种专利已过期的知名药物,易于老药新用。
研究设计与样本
- DEXA-PSYCH试验是一项由研究者发起的双盲、随机、安慰剂对照、平行组优效性试验。
- 300例符合中重度抑郁标准的参与者按1:1比例随机接受1周地塞米松(4 mg/日×4天,随后2 mg/日×3天)或安慰剂作为常规治疗的附加治疗。
- 住院和门诊患者均可入选;排除标准包括但不限于精神病性障碍、双相障碍和糖尿病。
主要发现
- 主要结局为第7天蒙哥马利-阿斯伯格抑郁评定量表(MADRS)评分较基线的变化,将通过意向性分析中的重复测量混合模型(MMRM)进行分析。
- 关键次要结局包括应答率和缓解率、干预后3周疗效、对生活质量的影响以及安全性结局。
- 其他次要结局包括整体功能、疲劳、焦虑、劳动力市场归属以及炎症生物标志物与治疗应答之间的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally, depression represents one of the leading causes of years lived with disability. The effects of current pharmacological treatments are small-to-moderate and often delayed by weeks. Immunological disturbances have been associated with depression and meta-analyses have suggested that anti-inflammatory agents have moderate-to-large anti-depressant effects. The largest effects were reported for glucocorticoids. However, previous trials were too small to legitimize standard use of glucocorticoids as add-on treatment in depression. The purpose of the DEXA-PSYCH study is to investigate the effect and safety of short-term, oral dexamethasone compared to placebo as add-on therapy in moderate-to-severe depression. METHODS: The DEXA-PSYCH trial is an investigator-initiated, double-blind, randomized, placebo-controlled, parallel-group superiority trial. Three-hundred participants meeting criteria for moderate-to-severe depression will be randomized in a 1:1 ratio to 1 week of either dexamethasone (4 mg/day for 4 days, subsequently 2 mg/day for 3 days) or placebo as add-on treatment to treatment as usual. Both in- and out-patients are eligible. Exclusion criteria include, but are not limited to, psychotic disorders, bipolar disorder, and diabetes. The primary outcome is change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score on day 7 and will be analyzed through a Mixed Model for Repeated Measurements (MMRM) in an intention-to-treat analysis. Key secondary outcomes include response and remission rates, efficacy 3 weeks after the intervention, effects on quality of life, and safety outcomes. Other secondary outcomes include overall functioning, fatigue, anxiety, labor-market affiliation, and associations between inflammatory biomarkers and treatment response. DISCUSSION: The DEXA-PSYCH trial represents the largest trial of its kind globally. If the trial confirms findings from previous, smaller studies, short-term oral dexamethasone could become an attractive augmentation strategy if acute anti-depressant effects are warranted. Dexamethasone is an off-patent, well-known drug readily repurposed for new indications. TRIAL REGISTRATION: EU Clinical Trials Number 2022-501428-45-00, Registered 25th of July 2022 in the EU Clinical Trials Information System ( https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-501428-45-00 ). WHO Universal Trial Identifier U1111-1280-7614.
引用
- Rømer TB, Frederiksen CG, Hansen PB, et al. The DEXA-PSYCH Study-dexamethasone for moderate-to-severe depression: study protocol for a double-blind, randomized, parallel-group, placebo-controlled trial. Trials. 2025. PMID: 40855339. doi:10.1186/s13063-025-08989-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。